Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients (original) (raw)

Abstract

A novel influenza A (H7N9) virus of avian origin emerged in eastern China in the spring of 2013. This virus causes severe disease in humans, including acute and often lethal respiratory failure. As of January 2014, 275 cases of H7N9-infected patients had been reported, highlighting the urgency of identifying biomarkers for predicting disease severity and fatal outcomes. Here, we show that plasma levels of angiotensin II, a major regulatory peptide of the renin–angiotensin system, are markedly elevated in H7N9 patients and are associated with disease progression. Moreover, the sustained high levels of angiotensin II in these patients are strongly correlated with mortality. The predictive value of angiotensin II is higher than that of C-reactive protein and some clinical parameters such as the PaO2/FiO2 ratio (partial pressure of arterial oxygen to the fraction of inspired oxygen). Our findings indicate that angiotensin II is a biomarker for lethality in flu infections.

Similar content being viewed by others

Introduction

The avian influenza pandemic poses a potentially grave public health threat because of the high mortality rates observed in infected people1,2,3,4,5. Generally, the numbers of cases from single hospitals are limited and insufficient for statistical analysis6. As a result, no biomarker that predict disease progression and outcomes of potentially lethal flu infections has been identified7. During the spring of 2013, a novel and highly virulent avian-origin influenza A subtype virus, H7N9, emerged and spread among humans in Eastern China5,8,9,10. In total, 144 people were infected by the end of 2013, and there were already over 100 newly infected patients before the end of January in 2014. Of the 111 patients we previously studied in 2013, 76.6% were admitted to an intensive care unit1. Among these patients, more than 70% developed acute respiratory distress syndrome (ARDS)1, which was associated with high mortality, as few interventions were available11,12. Although extensive therapeutic interventions were employed, including antiviral treatments, oxygen therapy, mechanical ventilation, antibiotics, glucocorticoids, intravenous immunoglobulins, extracorporeal membrane oxygenation, continuous renal replacement therapy and artificial liver support system therapy, we observed high mortality rates among H7N9-infected patients1,13,14,15.

Our previous studies on sepsis, aspiration and severe acute respiratory syndrome coronavirus-induced ARDS demonstrated that dysfunction of the renin–angiotensin system (RAS) is involved in the molecular pathogenesis of ARDS16,17. In essence, angiotensin-converting enzyme (ACE) 2 and angiotensin II type 2 receptor protect mice from ARDS, whereas ACE, angiotensin II, and angiotensin II type 1a receptor promote the impairment of lung function in mouse models16,17. Moreover, in our accompanying paper18, we show that ACE2-mutant mice die more rapidly after H5N1 infection and that recombinant ACE2 can partially protect mice from lethal H5N1 infection.

For the first time, we have gained access to samples from a large cohort of H7N9-infected patients. Therefore, we asked whether dysfunction of the RAS is present in H7N9-infected patients. Here, we report that there is a highly positive linear association between plasma levels of angiotensin II in H7N9-infected patients and disease severity scores (Acute Physiology and Chronic Health Evaluation II, APACHE II)19,20, and that angiotensin II levels can predict fatal outcomes.

Results

Elevated angiotensin II levels may reflect disease outcomes

We collected plasma from 47 H7N9-infected patients who were diagnosed in Hangzhou (40), Nanjing (6) and Shanghai Autonomous City (1), China (Supplementary Fig. 1, Table 1). We also collected plasma from 21 swine-origin influenza (H1N1) virus-infected patients in Beijing from December 2012 to February 2013 (Supplementary Table 1). The presence of H7N9 and H1N1 influenza viruses was confirmed by PCR. Plasma from six healthy volunteers from the China CDC who were considered to be at high risk for H7N9 infection and plasma from 46 coronary heart disease (CHD) patients in Beijing were collected from April 2013 to June 2013. The characteristics of the study subjects are shown in Supplementary Tables 2–4. To stratify the distinct time points during the illness, plasma was obtained within the first 7 days of disease onset (H7N9: _n_=24; H1N1: _n_=10), between 8 and 14 days following disease onset (H7N9: _n_=11; H1N1: _n_=7), and during the recovery phase from 15 days after disease onset (H7N9: _n_=11; H1N1: _n_=4) (Fig. 1a). Intriguingly, at all stages, angiotensin II plasma levels were markedly higher in H7N9-infected patients than in H1N1-infected patients, all CHD patients, and CHD patients with a diagnosis of hypertension (Fig. 1a, Table 1, Supplementary Tables 1–4). Angiotensin II levels in plasma from H1N1-infected patients obtained during the first week of disease were moderately higher than in those obtained from healthy individuals, whereas angiotensin II levels in plasma obtained during other time periods from H1N1-infected patients and CHD patients were not significantly different from those of high-risk healthy individuals (Fig. 1a, Supplementary Table 4). Notably, angiotensin II levels decreased in H7N9-infected patient plasma harvested 15 days after disease onset, suggesting that angiotensin II levels may be related to disease severity in the early stage of avian influenza H7N9 infection (Fig. 1a, Supplementary Table 4).

Table 1 Characteristics of the 35 patients with H7N9 virus infection.

Full size table

Figure 1: Angiotensin II levels are increased in plasmas of H7N9-infected patients.

Among the study participants, 46 patients were infected with avian-origin H7N9 Influenza A virus (A-OIV H7N9) and 21 were infected with swine-origin H1N1 influenza A virus (S-OIV H1N1). In addition, six healthy volunteers, 46 CHD patients and 35 CHD patients with hypertension were recruited as controls. (a) Angiotensin II levels in plasma of healthy controls, CHD group, CHD with hypertension group, and during H7N9 or H1N1 infection. The number of infected individuals for each group was: day 0–7 group (H7N9: _n_=24; H1N1: _n_=10), day 8–14 group (H7N9: _n_=11; H1N1: _n_=7) and day 15 group (H7N9: _n_=11; H1N1: _n_=4). The horizontal lines represent the median value in each group. Detailed statistical information is shown in Supplementary Table 4. (b) Angiotensin II plasma levels at week 1 and week 2 in H7N9-infected patients hospitalized less than 28 days (_n_=11), hospitalized longer than 28 days (_n_=6) and deceased (_n_=5). The horizontal lines represent the mean value in each group. All experiments were in duplicate. Mann–Whiney U test and Wilcoxon matched-pair test were used in the statistics. *P<0.05, **P<0.01, ***P<0.001.

Full size image

To investigate whether changes in angiotensin II levels among H7N9-infected patients are associated with disease progression and/or outcome, we analysed angiotensin II levels in 22 H7N9-infected patients for whom serially collected of plasma samples from both the first and second week of illness were available (Fig. 1b). These 22 H7N9-infected patients were divided into three groups according to disease outcome: patients who were discharged from the hospital within 28 days, patients who were discharged from the hospital after more than 28 days and patients who died (Fig. 1b). Interestingly, in the group of patients discharged from the hospital within 28 days, plasma angiotensin II levels significantly decreased during the second week of illness compared with the first week. However, in the group of patients hospitalized for a longer period or who died, plasma angiotensin II levels remained high during the second week of illness (Fig. 1b). Therefore, plasma angiotensin II levels in H7N9-infected patients may stratify disease severity and may be predictive of disease outcome.

Angiotensin II levels are correlated with viral load

We next analysed the potential correlation between patient plasma angiotensin II levels and viral load, APACHE II score and mortality using samples from a total of 35 H7N9-infected patients. These samples included the above mentioned 22 H7N9-infected patients with both week 1 and week 2 plasma samples plus two patients with week 1 samples only and 11 patients with week 2 plasma samples only. In parallel, we used viral cycle threshold (Ct) values from H1N1-infected patients (10 patient samples from week 1 and 7 patient samples from week 2) to calculate the correlation.

To establish viral load, we collected pharyngeal samples on the same day as plasma collection from 21 H7N9 patients during the first week of illness and 30 H7N9 patients during the second week of illness. Viral loads were determined using Ct values for the H7N9-specific haemagglutinin gene by quantitative real-time reverse transcription-PCR as previously described21,22. We excluded samples with Ct values that indicated negative viral load. Pearson correlation analysis showed that plasma angiotensin II levels were indeed negatively correlated with H7N9 virus Ct values (and thus, positively correlated with viral load) during week 1, but not week 2 of illness (Supplementary Table 5). Our data suggested that elevations of angiotensin II levels in the plasmas of H7N9-infected patients harvested during week 1 of disease onset were induced by avian influenza H7N9 virus. Interestingly, we also discovered a high linear correlation between H1N1 viral Ct value and angiotensin II levels in the plasma of patients infected with H1N1 collected at week 1 but not week 2 of disease onset (Supplementary Table 5). Although the angiotensin II levels in plasmas from H1N1-infected patients were significantly lower than those in plasmas of H7N9-infected patients, the elevations of angiotensin II levels in plasmas harvested at the first week of disease onset was induced by swine-origin influenza virus H1N1 (Supplementary Table 5).

Angiotensin II levels are associated with disease severity

APACHE II scores were determined to evaluate disease severity on the first day in the intensive care unit19,20. Plasma angiotensin II levels in H7N9 patients during the second week of illness demonstrated a high and significantly positive linear correlation with APACHE II scores, whereas angiotensin II levels during the first week of illness showed a weaker, albeit significant, positive linear correlation with disease severity (Fig. 2). Again, plasma angiotensin II levels of H1N1-infected patients were positively correlated with patient APACHE II scores; however, the Spearman rank coefficient correlation did not pass hypothesis testing (Supplementary Fig. 2). Our results suggest a potential therapeutic strategy that would involve decreasing angiotensin II plasma levels during H7N9 infections.

Figure 2: APACHE II scores are highly positively correlated with plasma angiotensin II levels in H7N9-infected patients.

APACHE II scores from 21 and 32 avian-origin H7N9 Influenza A virus (A-OIV H7N9)-infected patients were available for the first and second week’s correlation analysis, respectively. Spearman rank correlation analysis (ρ) and P value are provided in each graph.

Full size image

Angiotensin II levels at week 2 can predict fatal outcomes

We further analysed whether angiotensin II levels were linked to fatal outcomes. Indeed, plasma angiotensin II levels during the second week of H7N9 illness were statistically significantly higher in the group of patients who died compared with the group who were discharged from the hospital within 28 days (Fig. 3). Most swine-origin influenza A (H1N1) virus infections were not fatal. Among the 21 H1N1-infected patients we studied, one patient died and 19 patients were released from the hospital within 28 days.

Figure 3: Fatal outcome is linked to high plasma levels of angiotensin II in H7N9-infected patients.

Angiotensin II concentrations in plasma from the first and second week of illness caused by avian-origin H7N9 Influenza A virus (A-OIV H7N9) in different outcome groups. The number of patients and the time-period in which they died are as follows. Patients with plasma harvested during the first week of illness: patients hospitalized less than 28 days (_n_=12), death (_n_=5). Patients with plasma harvested during the second week of illness: patients hospitalized less than 28 days (_n_=16), death (_n_=8). The horizontal lines represent the median value in each group. Mann–Whiney U test was used in the statistics. *P<0.05.

Full size image

We performed biostatistical analyses to confirm angiotensin II as a biomarker of fatal outcome. We first used SPSS software to calculate its predictive value of fatal outcome (Supplementary Table 6). In addition to angiotensin II, we also included a biomarker for infectious disease C-reactive protein, and clinical parameters of pneumonia severity index score and SMART-COP in the analysis23,24. The area under the curve of plasma angiotensin II levels during the second week of illness among H7N9-infected patients was 0.875, and the predictive values of C-reactive protein, pneumonia severity index score and SMART-COP were all less significant than angiotensin II (Fig. 4, Supplementary Table 6). Our data suggested that angiotensin II level at the week 2 of disease onset could predict the fatal outcome. We also used MedCalc software and the results were the same (Supplementary Table 7). The sensitivity and specificity of this analysis were 87.5% and 68%, respectively (Supplementary Table 7). In addition, the positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio within 95% confidence intervals were determined (Supplementary Table 7).

Figure 4: Receiver operating characteristic (ROC) curve of plasma angiotensin II levels and other biomarkers during the second week of H7N9 infection.

ROC curve of the plasma angiotensin II levels, C-reactive protein (CRP), PaO2/FiO2 ratios, pneumonia severity index (PSI) scores and SMART-COP scores in the second week of avian-origin H7N9 Influenza A virus (A-OIV H7N9) infection are shown. Detailed information on the area under the ROC curve (AUC), the cut-off values, sensitivity, specificity, the positive predictive value (PPV), the negative predictive value (NPV), the positive likelihood ratio (PLR), the negative likelihood ratio (NLR) and Youden’s index are shown in Supplementary Tables 6–11.

Full size image

Using logistic regression analysis, we further analysed the independent predictor for fatal outcome among patients with H7N9 infections. Angiotensin II levels in plasma harvested during the second week of illness were determined to be an independent predictor among the clinical parameters of H7N9-infected patients including hypertension (Table 2). Taken together, these results suggest that plasma angiotensin II levels, especially during the second week of illness, are an indicator of disease severity among H7N9-infected patients and are positively associated with mortality.

Table 2 Logistic regression analysis of independence outcome predictor for plasma angiotensin II level independency in H7N9-infected patients during the second week of illness onset.

Full size table

Discussion

Angiotensin II is an octapeptide that is a potent vasopressor and a powerful stimulus for the production and release of aldosterone from the adrenal cortex25,26,27,28,29. Angiotensin II is a major substrate of the RAS29,30,31. Previous studies have shown that RAS has important roles in cardiovascular disease, neurodegenerative disorders, and importantly, acute lung injury16,32,33,34,35,36,37,38,39. In our study, we reveal for the first time that angiotensin II levels in human blood are associated with H7N9-induced disease severity and may potentially predict patient mortality. However, the limitation of this study is its retrospective nature, and further studies of additional potential biomarkers in patient plasma are needed in the future.

For historical reasons, there is currently no clinical biomarker to predict fatal outcome for lethal virus infection. In addition to the lack of a sufficiently sized cohort for standard statistical analysis, fatal outcomes usually result from multiorgan failure and are therefore difficult to associate with changes in a single protein in human plasma. Angiotensin II in the RAS has functions in multiple organs; it is indeed a likely biomarker that can be used to predict fatal outcome in lethal diseases.

Together with our accompanying paper describing treatment options18, these results raise the intriguing possibility that therapies targeting RAS may represent viable strategies for treating this deadly disease. In addition to recombinant human angiotensin-converting enzyme 2 (in clinical trial), angiotensin II lowering drugs, including ACE inhibitors and angiotensin II receptor blockers, are clinically available40,41. Future studies are necessary to determine the therapeutic effects of the proposed RAS targeting drugs in lethal virus infections.

Methods

Clinical specimens

H7N9-infected patients were recruited at the First Affiliated Hospital, College of Medicine, Zhejiang University (_n_=40), Jiangsu province (_n_=6) and Shanghai city (_n_=1). H1N1-infected patients were recruited from December 2012 to February 2013 at Beijing Chao-yang Hospital, Capital Medical University (_n_=21). Six healthy volunteers who were considered at high risk for H7N9 infection by the Chinese Center for Disease Control and Prevention (China CDC) and 46 CHD patients, including 35 CHD patients with a diagnosis of hypertension, from Peking Union Medical College Hospital (PUMCH) during the same period were recruited as controls. Clinical information was collected by attending physicians on the same day as plasma sampling. Basic clinical information and treatments are shown in Table 1, Supplementary Tables 1–4. Blood samples were collected using EDTA-anticoagulant tubes and centrifuged to obtain the plasma. H7N9-infected patient plasma was collected at least twice while in the hospital, including where possible one sample during the first week and one sample during the second week of illness onset after admission to the hospital. Patient sputum was collected on the same day. We used TaqMan real-time reverse transcription-PCR under standard thermal cycling conditions to detect M, H7, and N9 genes specific to the H7N9 influenza virus and H1 and N1 genes specific to the H1N1 influenza virus1,42,43. All specimens were stored at −80 °C until analysis. Informed written consents were obtained from all participants before enrolment in the study. This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of the First Affiliated Hospital of Zhejiang University, Beijing Chao-yang Hospital, China CDC and PUMCH.

Measurement of angiotensin II in patient plasma

The plasma concentration of angiotensin II was measured by ELISA according to the manufacturer’s instructions (RapidBio Lab, USA). All experiments were performed in a biosafety level 2 laboratory and in duplicates.

Statistical analysis

The Mann–Whitney U test or _χ_2-test was used to determine differences between two groups. Wilcoxon matched-pair tests were employed to assess differences between the first and the second week of disease onset among the same patients. The Pearson correlation coefficient and Spearman rank correlation coefficient were used for linear correlation analysis. We calculated receiver operating characteristic curves for predictive analysis. Logistic regression was used for independent predictor analysis. Mann–Whitney U test, _χ_2-test, Wilcoxon matched-pair test, Pearson correlation coefficient analysis, Spearman rank correlation coefficient analysis and Logistic regression analysis were performed with SPSS 16.0 for Windows (SPSS, Inc.). Receiver operating characteristic curves calculation was performed with SPSS 16.0 for Windows and MedCalc Software. A _P_-value<0.05 was considered statistically significant.

Additional information

How to cite this article: Huang, F. et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat. Commun. 5:3595 doi: 10.1038/ncomms4595 (2014).

References

1. Gao, H. N. et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. New Engl. J. Med. 368, 2277–2285 (2013).
   Article CAS Google Scholar
2. Peiris, J. S., de Jong, M. D. & Guan, Y. Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 20, 243–267 (2007).
   Article Google Scholar
3. Horimoto, T. & Kawaoka, Y. Pandemic threat posed by avian influenza A viruses. Clin. Microbiol. Rev. 14, 129–149 (2001).
   Article CAS Google Scholar
4. Fouchier, R. et al. Preventing pandemics: the fight over flu. Nature 481, 257–259 (2012).
   Article Google Scholar
5. Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. New Engl. J. Med. 368, 1888–1897 (2013).
   Article CAS Google Scholar
6. Bellomo, R., Warrillow, S. J. & Reade, M. C. Why we should be wary of single-center trials. Crit. Care. Med. 37, 3114–3119 (2009).
   Article Google Scholar
7. Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug. Discov. 2, 566–580 (2003).
   Article CAS Google Scholar
8. Wu, Y. & Gao, G. F. Lessons learnt from the human infections of avian-origin influenza A H7N9 virus: live free markets and human health. Sci. China. Life. Sci. 56, 493–494 (2013).
   Article Google Scholar
9. Li, J. et al. Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human. Sci. China. Life. Sci. 56, 485–492 (2013).
   Article CAS Google Scholar
10. Gao, G. F. & Wu, Y. Haunted with and hunting for viruses. Sci. China. Life. Sci. 56, 675–677 (2013).
    Article Google Scholar
11. Ichikawa, A. et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am. J. Respir. Crit. Care. Med. 187, 65–77 (2013).
    Article CAS Google Scholar
12. Morita, M. et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 153, 112–125 (2013).
    Article CAS Google Scholar
13. Li, Q. et al. Preliminary report: epidemiology of the avian influenza A (H7N9) outbreak in China. New Engl. J. Med. 370, 520–532 (2013).
    Article ADS Google Scholar
14. Hu, Y. et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381, 2273–2279 (2013).
    Article Google Scholar
15. Yu, L. et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin. Infect. Dis. 57, 1449–1457 (2013).
    Article CAS Google Scholar
16. Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112–116 (2005).
    Article ADS CAS Google Scholar
17. Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005).
    Article CAS Google Scholar
18. Zou, Z. et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat. Commun. 5, 3594 (2014).
    Article CAS Google Scholar
19. Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: a severity of disease classification system. Crit. Care. Med. 13, 818–829 (1985).
    Article CAS Google Scholar
20. LeGall, J. R., Loirat, P. & Alperovitch, A. APACHE II—a severity of disease classification system. Crit. Care. Med. 14, 754–755 (1986).
    CAS PubMed Google Scholar
21. Saiki, R. K. et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350–1354 (1985).
    Article ADS CAS Google Scholar
22. Kubista, M. et al. The real-time polymerase chain reaction. Mol. Aspects. Med. 27, 95–125 (2006).
    Article CAS Google Scholar
23. Fine, M. J. et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl. J. Med. 336, 243–250 (1997).
    Article CAS Google Scholar
24. Charles, P. G. et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin. Infect. Dis. 47, 375–384 (2008).
    Article Google Scholar
25. Murphy, T. J., Alexander, R. W., Griendling, K. K., Runge, M. S. & Bernstein, K. E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351, 233–236 (1991).
    Article ADS CAS Google Scholar
26. Aguilera, G., Schirar, A., Baukal, A. & Catt, K. J. Circulating angiotensin II and adrenal receptors after nephrectomy. Nature 289, 507–509 (1981).
    Article ADS CAS Google Scholar
27. Nikiforovich, G. V., Vesterman, B., Betins, J. & Podins, L. The space structure of a conformationally labile oligopeptide in solution: angiotensin. J. Biomol. Struct. Dyn. 4, 1119–1135 (1987).
    Article CAS Google Scholar
28. Gigante, B. et al. Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Hypertension 30, (3 Pt 2): 563–568 (1997).
    Article CAS Google Scholar
29. Peach, M. J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 57, 313–370 (1977).
    Article CAS Google Scholar
30. Sata, M. & Fukuda, D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J. Med. Invest. 57, 12–25 (2010).
    Article Google Scholar
31. Inagami, T. et al. Cloning, expression and regulation of angiotensin II receptors. Adv. Exp. Med. Biol. 377, 311–317 (1995).
    Article CAS Google Scholar
32. Morrell, N. W. & Stenmark, K. R. The renin-angiotensin system in pulmonary hypertension. Am. J. Respir. Crit. Care. Med. 187, 1138–1139 (2013).
    Article Google Scholar
33. Hsueh, W. A. & Wyne, K. Renin-angiotensin-aldosterone system in diabetes and hypertension. J. Clin. Hypertens. (Greenwich) 13, 224–237 (2011).
    Article CAS Google Scholar
34. Covic, A. & Gusbeth-Tatomir, P. The role of the renin-angiotensin-aldosterone system in renal artery stenosis, renovascular hypertension, and ischemic nephropathy: diagnostic implications. Prog. Cardiovasc. Dis. 52, 204–208 (2009).
    Article CAS Google Scholar
35. Savaskan, E. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr. Alzheimer. Res. 2, 29–35 (2005).
    Article CAS Google Scholar
36. Mogi, M. & Horiuchi, M. Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases. Geriatr. Gerontol. Int. 13, 13–18 (2013).
    Article Google Scholar
37. Shrikrishna, D., Astin, R., Kemp, P. R. & Hopkinson, N. S. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin. Sci. (Lond) 123, 487–498 (2012).
    Article CAS Google Scholar
38. Jiang, J. S. et al. Activation of the renin-angiotensin system in hyperoxia-induced lung fibrosis in neonatal rats. Neonatology 101, 47–54 (2012).
    Article CAS Google Scholar
39. Sato, T. et al. Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest. 123, 5203–5211 (2013).
    Article CAS Google Scholar
40. Tsutamoto, T. et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens. Res. 33, 118–122 (2010).
    Article CAS Google Scholar
41. Zhuo, J. L., Mendelsohn, F. A. & Ohishi, M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 39, (2 Pt 2): 634–638 (2002).
    Article CAS Google Scholar
42. Li, C. et al. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell. Res. 22, 528–538 (2012).
    Article ADS CAS Google Scholar
43. Wang, W. et al. Monoclonal antibody against CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury. Cell. Res. 23, 577–580 (2013).
    Article CAS Google Scholar

Download references

Acknowledgements

We thank the medical and nursing staff of First Affiliated Hospital, College of Medicine, Zhejiang University for their assistance in this study and their excellent care of patients diagnosed with influenza A H7N9 virus. We would like to thank Ke Wang and Shan Wang for their technical support. This work was funded by the Ministry of Science and Technology (2009CB522105 and 2011ZX09307-001-01), the Technology Group Project for Infectious Disease Control of Zhejiang Province (No.: 2009R50041) and the Fundamental Research Funds for the Central Universities as well as an intramural special grant for influenza virus research from the Chinese Academy of Sciences (KSZD-EW-Z-002). This work was also funded by the Natural Science Foundation of China (NSFC grants 81300057, 81373141 and 81230002), the Ministry of Health (201302017), the Ministry of Education (Biotherapy of 2011 innovation) and 111 project (B08007). J.M.P. was supported by the Austrian Academy of Sciences and an EU Advanced ERC grant. G.F.G is a leading principal investigator of the NSFC Innovative Research Group (grant 81321063).

Author information

Author notes

1. Fengming Huang, Jing Guo, Zhen Zou, Jun Liu, Bin Cao and Shuyang Zhang: These authors contributed equally to this work

Authors and Affiliations

1. Department of Biochemistry, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Tsinghua University, Beijing, 100005, China
   Fengming Huang, Zhen Zou, Wei Wang, Miaomiao Sheng, Song Liu, Yan Zhao, Qiang Liu, Huandi Zhou, Jindong Zhu & Chengyu Jiang
2. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
   Jing Guo, Guirong Qian, Xinjun Hu, Yuanting Chen, Yu Chen, Hainv Gao, Shigui Yang, Xiaoli Liu, Shufa Zheng, Jiezuan Yang, Hongyan Diao, Hongcui Cao & Lanjuan Li
3. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, China
   Jing Guo, Guirong Qian, Xinjun Hu, Yuanting Chen, Yu Chen, Hainv Gao, Shigui Yang, Xiaoli Liu, Shufa Zheng, Jiezuan Yang, Hongyan Diao, Hongcui Cao, George F. Gao & Lanjuan Li
4. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China
   Jun Liu, Ying Wu, Min Zhao, Shuguang Tan & George F. Gao
5. National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
   Jun Liu & George F. Gao
6. Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, 100020, China
   Bin Cao & Hui Li
7. Center for Translational Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100730, China
   Shuyang Zhang, Dan Guo, Yingchun Xu & Chengyu Jiang
8. Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100730, China
   Shuyang Zhang, Xiliang Zhao, Yicong Ye & Wei Wu
9. Hangzhou Center for Disease Control and Prevention, Hangzhou, 310021, China
   Jingcao Pan
10. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China
    Changjun Bao
11. Children’s Hospital Affiliated with Fudan University, Shanghai, 200032, China
    Mei Zeng
12. Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial, Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, China
    Haixia Xiao
13. Clinical Biobank, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100730, China
    Dan Guo & Yingchun Xu
14. IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr. Bohr-Gasse 3, Vienna, A-1030, Austria
    Josef M. Penninger
15. Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, China
    Dangsheng Li
16. Office of Director-General, Chinese Center for Disease Control and Prevention (China CDC), Beijing, 102206, China
    George F. Gao

Authors

1. Fengming Huang
   You can also search for this author inPubMed Google Scholar
2. Jing Guo
   You can also search for this author inPubMed Google Scholar
3. Zhen Zou
   You can also search for this author inPubMed Google Scholar
4. Jun Liu
   You can also search for this author inPubMed Google Scholar
5. Bin Cao
   You can also search for this author inPubMed Google Scholar
6. Shuyang Zhang
   You can also search for this author inPubMed Google Scholar
7. Hui Li
   You can also search for this author inPubMed Google Scholar
8. Wei Wang
   You can also search for this author inPubMed Google Scholar
9. Miaomiao Sheng
   You can also search for this author inPubMed Google Scholar
10. Song Liu
    You can also search for this author inPubMed Google Scholar
11. Jingcao Pan
    You can also search for this author inPubMed Google Scholar
12. Changjun Bao
    You can also search for this author inPubMed Google Scholar
13. Mei Zeng
    You can also search for this author inPubMed Google Scholar
14. Haixia Xiao
    You can also search for this author inPubMed Google Scholar
15. Guirong Qian
    You can also search for this author inPubMed Google Scholar
16. Xinjun Hu
    You can also search for this author inPubMed Google Scholar
17. Yuanting Chen
    You can also search for this author inPubMed Google Scholar
18. Yu Chen
    You can also search for this author inPubMed Google Scholar
19. Yan Zhao
    You can also search for this author inPubMed Google Scholar
20. Qiang Liu
    You can also search for this author inPubMed Google Scholar
21. Huandi Zhou
    You can also search for this author inPubMed Google Scholar
22. Jindong Zhu
    You can also search for this author inPubMed Google Scholar
23. Hainv Gao
    You can also search for this author inPubMed Google Scholar
24. Shigui Yang
    You can also search for this author inPubMed Google Scholar
25. Xiaoli Liu
    You can also search for this author inPubMed Google Scholar
26. Shufa Zheng
    You can also search for this author inPubMed Google Scholar
27. Jiezuan Yang
    You can also search for this author inPubMed Google Scholar
28. Hongyan Diao
    You can also search for this author inPubMed Google Scholar
29. Hongcui Cao
    You can also search for this author inPubMed Google Scholar
30. Ying Wu
    You can also search for this author inPubMed Google Scholar
31. Min Zhao
    You can also search for this author inPubMed Google Scholar
32. Shuguang Tan
    You can also search for this author inPubMed Google Scholar
33. Dan Guo
    You can also search for this author inPubMed Google Scholar
34. Xiliang Zhao
    You can also search for this author inPubMed Google Scholar
35. Yicong Ye
    You can also search for this author inPubMed Google Scholar
36. Wei Wu
    You can also search for this author inPubMed Google Scholar
37. Yingchun Xu
    You can also search for this author inPubMed Google Scholar
38. Josef M. Penninger
    You can also search for this author inPubMed Google Scholar
39. Dangsheng Li
    You can also search for this author inPubMed Google Scholar
40. George F. Gao
    You can also search for this author inPubMed Google Scholar
41. Chengyu Jiang
    You can also search for this author inPubMed Google Scholar
42. Lanjuan Li
    You can also search for this author inPubMed Google Scholar

Contributions

L.L., C.J and G.F.G. conceived the project. J.G., J.L., J.P., C.B., Mei Z., H.X., G.Q., X.H., Yuanting.C., Yu.C., H.G., S.Y., X.L., Shufa Z., J.Y., H.D., Y.W., Min Z., S.T. and H.C. collected clinical samples and specimens from H7N9-infected patients. B.C. and H.L. collected clinical samples from H1N1-infected patients. Shuyang Z., D.G., Y.X., W. Wu., Y.Y. and X.Z. collected clinical samples from CHD patients. Z.Z., J.G., J.L., W. Wang, S.L., Y.Z., Q.L., H.Z. and J.Z. performed the experiments. F.H., S.L. and W. Wang. analysed the data. D.L. and J.M.P. contributed to fruitful discussions and key ideas. C.J. wrote the manuscript and D.L., Z.Z., J.G., F.H., G.F.G., J.M.P., B.C. and L.L. revised the manuscript.

Corresponding authors

Correspondence toGeorge F. Gao, Chengyu Jiang or Lanjuan Li.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Huang, F., Guo, J., Zou, Z. et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients.Nat Commun 5, 3595 (2014). https://doi.org/10.1038/ncomms4595

Download citation

• Received: 04 September 2013
• Accepted: 07 March 2014
• Published: 06 May 2014
• DOI: https://doi.org/10.1038/ncomms4595

This article is cited by